Focus a minute on PFM’s website, and discussion in news and events by Dr. Messerschmidt of Precision Oncology on cost of new CAR-T therapies initiated by NVS and GILD. That discussion appeared in publications in October also, along with its acquisition of Epiontis, and the new financing PR in December.
PFM seems to have a lot of arms working world-wide.
Market Data 
Markets 
AI
